223 related articles for article (PubMed ID: 17561876)
1. Use of complementary and alternative medicines among a multistate, multisite cohort of people living with HIV/AIDS.
Josephs JS; Fleishman JA; Gaist P; Gebo KA;
HIV Med; 2007 Jul; 8(5):300-5. PubMed ID: 17561876
[TBL] [Abstract][Full Text] [Related]
2. Complementary and alternative medicine use in British Columbia--a survey of HIV positive people on antiretroviral therapy.
Dhalla S; Chan KJ; Montaner JS; Hogg RS
Complement Ther Clin Pract; 2006 Nov; 12(4):242-8. PubMed ID: 17030295
[TBL] [Abstract][Full Text] [Related]
3. Alternative medicine use in HIV-positive men and women: demographics, utilization patterns and health status.
Standish LJ; Greene KB; Bain S; Reeves C; Sanders F; Wines RC; Turet P; Kim JG; Calabrese C
AIDS Care; 2001 Apr; 13(2):197-208. PubMed ID: 11304425
[TBL] [Abstract][Full Text] [Related]
4. The incidence of and risk factors for HIV-associated cognitive-motor complex among patients on HAART.
Jevtović Dj; Vanovac V; Veselinović M; Salemović D; Ranin J; Stefanova E
Biomed Pharmacother; 2009 Sep; 63(8):561-5. PubMed ID: 19026516
[TBL] [Abstract][Full Text] [Related]
5. Use of complementary and alternative medicine in HIV-infected subjects.
Agnoletto V; Chiaffarino F; Nasta P; Rossi R; Parazzini F
Complement Ther Med; 2006 Sep; 14(3):193-9. PubMed ID: 16911899
[TBL] [Abstract][Full Text] [Related]
6. Provider-based complementary and alternative medicine use among three chronic illness groups: associations with psychosocial factors and concurrent use of conventional health-care services.
Sirois FM
Complement Ther Med; 2008 Apr; 16(2):73-80. PubMed ID: 18514908
[TBL] [Abstract][Full Text] [Related]
7. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors.
Corral I; Quereda C; Moreno A; Pérez-Elías MJ; Dronda F; Casado JL; Muriel A; Masjuán J; Alonso-de-Leciñana M; Moreno S
Cerebrovasc Dis; 2009; 27(6):559-63. PubMed ID: 19390181
[TBL] [Abstract][Full Text] [Related]
8. Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study.
Di Giambenedetto S; Bracciale L; Colafigli M; Cattani P; Pinnetti C; Bacarelli A; Prosperi M; Fadda G; Cauda R; De Luca A
Antivir Ther; 2007; 12(5):835-9. PubMed ID: 17713168
[TBL] [Abstract][Full Text] [Related]
9. Use of alternative therapies by people living with HIV/AIDS in Australia.
de Visser R; Grierson J
AIDS Care; 2002 Oct; 14(5):599-606. PubMed ID: 12419109
[TBL] [Abstract][Full Text] [Related]
10. Alternative therapy use in HIV-infected patients receiving highly active antiretroviral therapy.
Risa KJ; Nepon L; Justis JC; Panwalker A; Berman SM; Cinti S; Wagener MM; Singh N
Int J STD AIDS; 2002 Oct; 13(10):706-13. PubMed ID: 12396542
[TBL] [Abstract][Full Text] [Related]
11. Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994-2005.
Buchacz K; Baker RK; Moorman AC; Richardson JT; Wood KC; Holmberg SD; Brooks JT;
AIDS; 2008 Jul; 22(11):1345-54. PubMed ID: 18580614
[TBL] [Abstract][Full Text] [Related]
12. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
[TBL] [Abstract][Full Text] [Related]
13. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.
Tai JH; Udoji MA; Barkanic G; Byrne DW; Rebeiro PF; Byram BR; Kheshti A; Carter JD; Graves CR; Raffanti SP; Sterling TR
J Infect Dis; 2007 Oct; 196(7):1044-52. PubMed ID: 17763327
[TBL] [Abstract][Full Text] [Related]
14. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
[TBL] [Abstract][Full Text] [Related]
15. Patients presenting with AIDS in the HAART era: a collaborative cohort analysis.
Mussini C; Manzardo C; Johnson M; Monforte Ad; Uberti-Foppa C; Antinori A; Gill MJ; Sighinolfi L; Borghi V; Lazzarin A; Miró JM; Sabin C;
AIDS; 2008 Nov; 22(18):2461-9. PubMed ID: 19005269
[TBL] [Abstract][Full Text] [Related]
16. Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy.
Golub ET; Benning L; Sharma A; Gandhi M; Cohen MH; Young M; Gange SJ
Clin Infect Dis; 2008 Jan; 46(2):305-12. PubMed ID: 18171267
[TBL] [Abstract][Full Text] [Related]
17. Use of complementary and alternative therapies by patients with human immunodeficiency virus disease in the era of highly active antiretroviral therapy.
Bica I; Tang AM; Skinner S; Spiegelman D; Knox T; Gorbach S; Wilson IB
J Altern Complement Med; 2003 Feb; 9(1):65-76. PubMed ID: 12676036
[TBL] [Abstract][Full Text] [Related]
18. Herb and supplement use in the US adult population.
Kennedy J
Clin Ther; 2005 Nov; 27(11):1847-58. PubMed ID: 16368456
[TBL] [Abstract][Full Text] [Related]
19. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of antiretroviral treatment in a South African program: a cohort study.
Fairall LR; Bachmann MO; Louwagie GM; van Vuuren C; Chikobvu P; Steyn D; Staniland GH; Timmerman V; Msimanga M; Seebregts CJ; Boulle A; Nhiwatiwa R; Bateman ED; Zwarenstein MF; Chapman RD
Arch Intern Med; 2008 Jan; 168(1):86-93. PubMed ID: 18195200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
